Wall Street analysts’ outlook for Phreesia Inc. (PHR)

Phreesia Inc. (NYSE: PHR) stock fell -0.65% on Friday to $19.96 against a previous-day closing price of $20.09. With 0.88 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.41 million shares. During the session, the Health Information Services company that operates in wider Healthcare sector, reached to the highest price of $20.11 whereas the lowest price it dropped to was $19.52. The 52-week range on PHR shows that it touched its highest point at $40.00 and its lowest point at $20.07 during that stretch. It currently has a 1-year price target of $36.27. Beta for the stock currently stands at 0.65.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of PHR was down-trending over the past week, with a drop of -8.86%, but this was down by -26.94% over a month. Three-month performance dropped to -40.31% while six-month performance fell -42.66%. The stock lost -30.31% in the past year, while it has lost -38.32% so far this year. A look at the trailing 12-month EPS for PHR yields -2.87 with Next year EPS estimates of -0.77. For the next quarter, that number is -0.36. This implies an EPS growth rate of -41.80% for this year and 47.60% for next year.

Float and Shares Shorts:

At present, 53.79 million PHR shares are outstanding with a float of 52.57 million shares on hand for trading. On Aug 30, 2023, short shares totaled 2.04 million, which was 3.69% higher than short shares on Jul 30, 2023. In addition to Mr. Chaim Indig as the firm’s Co-Founder, CEO & Director, Mr. Evan Roberts serves as its Co-Founder & COO.

Institutional Ownership:

Through their ownership of 95.71% of PHR’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 58.39% of PHR, in contrast to 38.18% held by mutual funds. Shares owned by individuals account for 22.40%. As the largest shareholder in PHR with 10.78% of the stake, Fidelity Management & Research Co holds 5,826,028 shares worth 5,826,028. A second-largest stockholder of PHR, The Vanguard Group, Inc., holds 4,285,403 shares, controlling over 7.93% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in PHR, holding 3,267,245 shares or 6.04% stake. With a 3.33% stake in PHR, the CS Invt. Fds. 2 – is the largest stakeholder. A total of 1,800,000 shares are owned by the mutual fund manager. The Fidelity Select Medical Technolog, which owns about 3.26% of PHR stock, is the second-largest Mutual Fund holder. It holds 1,760,000 shares valued at 50.11 million. Vanguard Total Stock Market ETF holds 2.90% of the stake in PHR, owning 1,567,811 shares worth 44.64 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for PHR since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With PHR analysts setting a high price target of $43.00 and a low target of $29.00, the average target price over the next 12 months is $36.07. Based on these targets, PHR could surge 115.43% to reach the target high and rise by 45.29% to reach the target low. Reaching the average price target will result in a growth of 80.71% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.

Summary of Insider Activity:

Insiders traded PHR stock several times over the past three months with 13 Buys and 10 Sells. In these transactions, 48,649 shares were bought while 12,751 shares were sold. The number of buy transactions has increased to 48 while that of sell transactions has risen to 106 over the past year. The total number of shares bought during that period was 496,272 while 410,191 shares were sold.